National Research Corporation
NASDAQ:NRCMedical - Healthcare Information Services
+$0.07 today
- Market cap
- $555.16M
- Beta
- 0.40
- P/E (TTM)
- 43.0
- EPS (TTM)
- $0.41
- Dividend yield
- 3.14%
Volume 0.09M
Average 0.11M
NRC Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
National Research CorporationNASDAQ: NRC
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $5.35M rose 46.1% year over year, ahead of the +16.7% change in trailing-twelve-month free cash flow. Sequentially, it fell 11.8% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.
Context
- Free cash flow amounted to 11.5% of revenue in FY2025, down 1.9 pp from a year earlier.
- Free cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +46.1% holds above the trailing-twelve-month pace of +16.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 15.74M USD
- Year-over-year change
- -17.9%
- 4-year CAGR
- -21.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.74M | -17.9% |
| FY2024 | 2024-12-31 | 19.18M | -14.1% |
| FY2023 | 2023-12-31 | 22.33M | -15.5% |
| FY2022 | 2022-12-31 | 26.43M | -35.3% |
| FY2021 | 2021-12-31 | 40.83M | — |
Free Cash Flow vs competitors
How NRC compares with its peers on the latest reported figures
- NRC's LTM Mar 2026 free cash flow of $17.43M is the 7th largest of the 8 companies compared; the peer median is $26.45M.
- Its year-over-year change of +16.7% is the 4th highest of 8, against a peer median of +8.1%.
- Free cash flow amounts to 12.6% of revenue for NRC, versus a peer median of 15.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $73.72M | +189.3% | — | 14.9% | |
| LTM Mar 2026 | $60.01M | +8.1% | +6.5% | 19.2% | |
| LTM Mar 2026 | $45.43M | -2.6% | -21.7% | 56.0% | |
CTEVClaritev Corporation | LTM Mar 2026 | $38.76M | -60.9% | — | 4.0% |
| LTM Mar 2026 | $37.06M | -22.6% | +10.8% | 15.6% | |
| LTM Mar 2026 | $26.45M | +65.3% | +29.8% | 21.3% | |
| LTM Mar 2026 | $17.43M | +16.7% | -15.9% | 12.6% | |
| LTM Mar 2026 | $9.17M | +194.8% | -83.5% | 3.0% | |
| Peer median (excluding NRC) | $26.45M | +8.1% | +6.5% | 15.6% | |
Competitors are the stored peer set for NRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M |
| Depreciation & Amortization | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M |
| Deferred Income Tax | 33K | (1.24M) | (717K) | (406K) | 2.45M |
| Stock-Based Compensation | 623K | 1.2M | 935K | 284K | 3.31M |
| Change in Working Capital | 1.84M | (3.35M) | 1.03M | 3.84M | 916K |
| Accounts Receivables | 343K | (733K) | 2.08M | 1.76M | (53K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 4K | (589K) | 184K | (108K) | 170K |
| Other Working Capital | 1.49M | (2.03M) | (1.24M) | 2.19M | 799K |
| Other Non-Cash Items | 7K | 2.58M | (102K) | 100K | 545K |
| Operating Cash Flow | 46.34M | 36.27M | 38.11M | 34.63M | 26.45M |
| Capital Expenditures | (5.51M) | (9.84M) | (15.78M) | (15.45M) | (10.71M) |
| Acquisitions (Net) | (3M) | 0 | 0 | (4.83M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 1K | 0 | 0 |
| Investing Cash Flow | (8.51M) | (9.84M) | (15.78M) | (20.28M) | (10.71M) |
| Debt Repayment | (4.59M) | (4.77M) | 14.18M | 25.99M | 16.11M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 132K |
| Common Stock Repurchased | (4.14M) | (27.62M) | (19.1M) | (30.95M) | (20.18M) |
| Dividends Paid | (9.16M) | (20.96M) | (36.37M) | (11.45M) | (10.98M) |
| Other Financing Activities | (275K) | (2.04M) | 576K | (359K) | (923K) |
| Financing Cash Flow | (18.16M) | (55.58M) | (40.71M) | (16.76M) | (15.84M) |
| Effect of Forex Changes | 3K | (182K) | (1K) | 0 | 0 |
| Net Change in Cash | 19.67M | (29.34M) | (18.37M) | (2.42M) | (94K) |
| Free Cash Flow | 40.83M | 26.43M | 22.33M | 19.18M | 15.74M |
National Research Corporation
NASDAQ:NRC
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.